iTeos Therapeutics (ITOS) News Today $8.32 +0.19 (+2.34%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Matthew Gall Acquires 5,000 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) StockNovember 20 at 6:24 AM | insidertrades.comWedbush Forecasts Higher Earnings for iTeos TherapeuticsNovember 17, 2024 | americanbankingnews.comPromising Developments and Strategic Positioning Drive Buy Rating for iTeos TherapeuticsNovember 15, 2024 | markets.businessinsider.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next YearNovember 15, 2024 | finance.yahoo.comiTeos Therapeutics' (ITOS) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a research report on Friday.November 15, 2024 | marketbeat.comWedbush Predicts Stronger Earnings for iTeos TherapeuticsiTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Equities researchers at Wedbush boosted their FY2024 earnings per share (EPS) estimates for iTeos Therapeutics in a research note issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earNovember 15, 2024 | marketbeat.comiTeos Therapeutics: Potential Upside from Adenosine Program Amidst TIGIT ChallengesNovember 14, 2024 | markets.businessinsider.comiTeos Therapeutics Reports Q3 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comStrategic Catalysts and Financial Stability Underpin Buy Rating for iTeos TherapeuticsNovember 13, 2024 | markets.businessinsider.comiTeos Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 12, 2024 | globenewswire.comBOXER CAPITAL, LLC Expands Stake in ITeos Therapeutics IncOctober 16, 2024 | finance.yahoo.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock Position Decreased by AQR Capital Management LLCAQR Capital Management LLC trimmed its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 66.0% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 29,298 shares of the company's stock after selling 56,870 sharesOctober 16, 2024 | marketbeat.comMillennium Management LLC Decreases Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)Millennium Management LLC lessened its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 72.7% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 241,305 shares of the company's stock after selling 641,676 sharesOctober 14, 2024 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest UpdateiTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) was the target of a significant increase in short interest in September. As of September 30th, there was short interest totalling 4,820,000 shares, an increase of 92.0% from the September 15th total of 2,510,000 shares. Based on an average daily volume of 518,700 shares, the short-interest ratio is presently 9.3 days. Currently, 17.2% of the company's stock are short sold.October 12, 2024 | marketbeat.comDimensional Fund Advisors LP Grows Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)Dimensional Fund Advisors LP increased its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 14.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 908,329 shares of the compOctober 6, 2024 | marketbeat.comTANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeutics IncSeptember 30, 2024 | finance.yahoo.com156,894 Shares in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Bought by Clearline Capital LPClearline Capital LP bought a new position in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 156,894 shares of the company's stock, valued at approximSeptember 29, 2024 | marketbeat.comRenaissance Technologies LLC Sells 157,700 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)Renaissance Technologies LLC trimmed its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 22.0% in the second quarter, according to its most recent filing with the SEC. The fund owned 559,600 shares of the company's stock after selling 157,700 shares during the period. RenaissancSeptember 25, 2024 | marketbeat.comInnate Pharma S.A. (IDD.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comPiper Sandler maintains Overweight rating on iTeos Therapeutics stockSeptember 18, 2024 | uk.investing.comWedbush Weighs in on iTeos Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:ITOS)iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Wedbush lifted their FY2027 earnings per share (EPS) estimates for shares of iTeos Therapeutics in a note issued to investors on Sunday, September 15th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($September 18, 2024 | marketbeat.comITeos Therapeutics Shares Rise on Positive Data From Lung Cancer StudySeptember 17, 2024 | marketwatch.comiTeos Therapeutics (ITOS) Receives a Buy from Piper SandlerSeptember 17, 2024 | markets.businessinsider.comiTeos Therapeutics' (ITOS) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $46.00 target price on shares of iTeos Therapeutics in a report on Monday.September 16, 2024 | marketbeat.comiTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGITSeptember 15, 2024 | seekingalpha.comBuy Rating Affirmed for iTeos Therapeutics Amid Promising Lung-201 Study OutcomesSeptember 14, 2024 | markets.businessinsider.comGSK, iTeos Lung Cancer Data Set to Reignite Hope for Drug ClassSeptember 14, 2024 | bloomberg.comiTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer PatientsSeptember 14, 2024 | globenewswire.comiTeos Therapeutics (NASDAQ:ITOS) Sees Large Volume IncreaseiTeos Therapeutics (NASDAQ:ITOS) Sees Unusually-High Trading VolumeSeptember 11, 2024 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Shares Up 8.2%iTeos Therapeutics (NASDAQ:ITOS) Trading 8.2% HigherSeptember 9, 2024 | marketbeat.comCandriam S.C.A. Invests $7.56 Million in iTeos Therapeutics, Inc. (NASDAQ:ITOS)Candriam S.C.A. bought a new stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 509,303 shares of the company's stock, valued at approximately $7,558,0September 9, 2024 | marketbeat.comiTeos Therapeutics Inc.: iTeos to Participate in Upcoming Investor ConferencesAugust 28, 2024 | finanznachrichten.deiTeos to Participate in Upcoming Investor ConferencesAugust 28, 2024 | globenewswire.comWe're Keeping An Eye On iTeos Therapeutics' (NASDAQ:ITOS) Cash Burn RateAugust 25, 2024 | sg.finance.yahoo.comiTeos Therapeutics (NASDAQ:ITOS) Shares Gap Up to $15.89iTeos Therapeutics (NASDAQ:ITOS) Shares Gap Up to $15.89August 20, 2024 | marketbeat.comiTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024August 20, 2024 | globenewswire.comITOS Sep 2024 13.000 put (ITOS240920P00013000)August 19, 2024 | finance.yahoo.comITOS Sep 2024 18.000 put (ITOS240920P00018000)August 17, 2024 | finance.yahoo.comiTeos Therapeutics (NASDAQ:ITOS) Stock Price Down 3%iTeos Therapeutics (NASDAQ:ITOS) Shares Down 3%August 16, 2024 | marketbeat.comWells Fargo Initiates Coverage of iTeos Therapeutics (ITOS) with Overweight RecommendationAugust 14, 2024 | msn.comWells Fargo & Company Begins Coverage on iTeos Therapeutics (NASDAQ:ITOS)Wells Fargo & Company began coverage on shares of iTeos Therapeutics in a research note on Tuesday. They set an "overweight" rating and a $31.00 price target on the stock.August 13, 2024 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) PT Lowered to $24.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. cut their price target on iTeos Therapeutics from $27.00 to $24.00 and set an "overweight" rating for the company in a report on Monday.August 12, 2024 | marketbeat.comiTeos Therapeutics Inc.: iTeos Reports Second Quarter 2024 Financial Results and Provides Business UpdatesAugust 9, 2024 | finanznachrichten.deBuy Rating Affirmed for iTeos Therapeutics on Strong Financials and Promising Pipeline UpdatesAugust 9, 2024 | markets.businessinsider.comiTeos Therapeutics (NASDAQ:ITOS) Rating Reiterated by WedbushWedbush restated an "outperform" rating and issued a $21.00 price objective on shares of iTeos Therapeutics in a research note on Thursday.August 8, 2024 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Shares Down 6.1% iTeos Therapeutics (NASDAQ:ITOS) Stock Price Down 6.1%August 8, 2024 | marketbeat.comiTeos Reports Second Quarter 2024 Financial Results and Provides Business UpdatesAugust 8, 2024 | markets.businessinsider.comiTeos Therapeutics names new Chief Medical OfficerAugust 7, 2024 | investing.comiTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical OfficerAugust 5, 2024 | globenewswire.comKennedy Capital Management LLC Acquires Shares of 145,734 iTeos Therapeutics, Inc. (NASDAQ:ITOS)Kennedy Capital Management LLC bought a new position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 145,734 shares of the company's stock, valued at approximately $1,988,0July 31, 2024 | marketbeat.com Get iTeos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter. Email Address JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late. ITOS Media Mentions By Week ITOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ITOS News Sentiment▼0.750.49▲Average Medical News Sentiment ITOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ITOS Articles This Week▼52▲ITOS Articles Average Week Get iTeos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TSHA News Today VXRT News Today CALT News Today RCKT News Today ANIP News Today MESO News Today AVDL News Today GYRE News Today APLT News Today COGT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ITOS) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
